Artivion Inc (AORT)vsEdwards Lifesciences Corp (EW)
AORT
Artivion Inc
$19.40
-3.48%
HEALTHCARE · Cap: $998.73M
EW
Edwards Lifesciences Corp
$105.80
-0.01%
HEALTHCARE · Cap: $59.81B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1285% more annual revenue ($6.67B vs $481.88M). EW leads profitability with a 15.3% profit margin vs -3.6%. EW appears more attractively valued with a PEG of 2.14. EW earns a higher WallStSmart Score of 54/100 (C-).
AORT
Hold35
out of 100
Grade: F
EW
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.3%
Fair Value
$31.25
Current Price
$19.40
$11.85 premium
Margin of Safety
+69.2%
Fair Value
$257.48
Current Price
$105.80
$151.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 30.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 4.9%
Expensive relative to growth rate
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Operating Margin.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.
Key Dynamics to Monitor
AORT profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.28 — expect wider price swings.
EW is growing revenue faster at 10.5% — sustainability is the question.
EW generates stronger free cash flow (507M), providing more financial flexibility.
Bottom Line
EW scores higher overall (54/100 vs 35/100), backed by strong 15.3% margins and 10.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?